Bavarian Nordic gets Greek govt smallpox vaccine contract
Denmark's Bavarian Nordic has been contracted to supply vaccines againstsmallpox by the Greek government.
In collaboration with the local drugmaker P N Gerolymatos, Bavarian will supply an undisclosed number of doses of its safe smallpox vaccine, MVA-BN (Modified Vaccinia Ankara - Bavarian Nordic), which can also be given to immune-compromised individuals. The vaccines are to be used in the event of an outbreak of smallpox in Greece and will be delivered within a short time, Bavarian has said.
The firm's chief executive, Peter Wulff, noted that, "since the tragic events of September 11, we have been in discussion with a number of other countries about supplying vaccines that will provide a safe and effective defence against the new threat of a global outbreak of smallpox."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze